John McCafferty, PhD

Chief Technology Officer at Maxion Therapeutics

Speaker

John McCafferty was one of the founders of Cambridge Antibody Technology (CAT) and a co-inventor of antibody phage display. In 2012 he formed IONTAS who generated multiple drug leads currently in clinical trial by partner companies. During this period John developed KnotBody^TM technology to address ion channels, an important target class which are under-served by biologics. He founded Maxion Therapeutics to take advantage of this drug development opportunity. Interspersed with company formation John has held academic positions at the Wellcome Trust Sanger Institute and is currently an Affiliated professor at the Department of Medicine at the University of Cambridge.